Pharmaceutical intermediates
Rimegepant Intermediates
6 pharmaceutical intermediates for Rimegepant. Indication: Migraine.
About Rimegepant
- Originator
- Bristol Myers Squibb
- Indication
- Migraine
- Approved Date
- 02/27/2020
- NCE Patent
- 02/27/2025
- DS/DP
- 03/09/2030
Available intermediates
6 intermediates currently listed for Rimegepant. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (5S,6S,9R)-6-(2,3-difluorophenyl)-9-((triisopropylsilyl)oxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-5-aminedihydrochloride | 1373116-04-1 | / | / |
| 7,8-dihydro-5H-cyclohepta[b]pyridine-5,9(6H)-dione | 39713-40-1 | / | / |
| (R)-9-((triisopropylsilyl)oxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-5-one hydrochloride | 1190363-45-1 | / | / |
| 1-(1-(1H-imidazole-1-carbonyl)piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one | 1373116-06-3 | / | / |
| (6S,9R)-6-(2,3-Difluorophenyl)-6,7,8,9-tetrahydro-9-[[tris(1-methylethyl)silyl]oxy]-5H-cyclohepta[b]pyridin-5-one | 1190363-46-2 | / | / |
| 1-piperidin-4-yl-3H-imidazo[4,5-b]pyridin-2-one,dihydrochloride | 781649-84-1 | / | / |
Other programs under R
Building toward Rimegepant?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →